Filing Flows

Filing Flows › Companies › Dogwood Therapeutics › Cash flow

Dogwood Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$4.6M in Q3 2026 · −$16.5M over twelve months

Operating cash flow−$4.6M
Free cash flow−$4.6M

Analysis

In Q3 2026, Dogwood Therapeutics generated −$4.6M of operating cash flow. That is $1.4M less than in Q3 2025 (−$3.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$16.5M; the largest uses were operating cash flow ($16.5M); besides operations, cash came from other financing ($11.3M); the cash balance fell by $5.2M.

Operating cash flow was −$4.6M against net income of −$4.9M. The largest differences: stock-based pay +$558K, accrued liabilities −$436K, prepaid and other assets +$319K.

Free cash flow

Dogwood Therapeutics: free cash flow by quarterDogwood Therapeutics: free cash flow by quarter−$6.1MQ4 2024−$4.7MQ1 2025−$4.0MQ2 2025−$3.3MQ3 2025−$3.6MQ4 2025−$4.6MQ1 2026−$3.6MQ2 2026−$4.6MQ3 2026
Operating cash flow less capital spending.
Dogwood Therapeutics: operating cash flow against capital spendingDogwood Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$6.1M$0Q4 2024−$4.7M$0Q1 2025−$4.0M$0Q2 2025−$3.3M$0Q3 2025−$3.6M$0Q4 2025−$4.6M$0Q1 2026−$3.6M$0Q2 2026−$4.6M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$4.6M, Capital spending $0.

Capital allocation, year by year

Dogwood Therapeutics: where the cash came from (up) and went (down), by fiscal yearDogwood Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedFY2021: Operating cash flow −$15.7MFY2021: Shares issued −$295KFY2021FY2022: Operating cash flow −$11.5MFY2022: Shares issued $4.5M$4.5MFY2022FY2023: Operating cash flow −$4.9MFY2023: Shares issued $1.2M$1.2MFY2023FY2024: Operating cash flow −$8.8MFY2024FY2025: Operating cash flow −$15.6MFY2025
Over these 5 years operating cash flow totalled −$56.4M; the largest uses were operating cash flow ($56.4M) and shares issued ($295K). Cash-flow statements as filed.

Where the cash came from and went

Dogwood Therapeutics: sources (+) and uses (−) of cash, Q3 2026Dogwood Therapeutics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$4.7MOperating cash flow−$4.6MExchange rates−$25KOther financing$50
Dogwood Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Dogwood Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$16.5MOther financing$11.3MCash drawn (+) / kept (−)$5.2MExchange rates−$31K

From profit to cash

Dogwood Therapeutics: net income to operating cash flow, Q3 2026Dogwood Therapeutics: net income to operating cash flow, Q3 2026Net income−$4.9MStock-based pay$558KDeferred taxes−$1KPayables−$246KAccrued liabilities−$436KPrepaid and other assets$319KOperating cash flow−$4.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q3 2026−$4.6M$4.7M−$4.6M
Q2 2026−$3.6M$3.6M−$3.6M
Q1 2026−$4.6M−$6.7M−$4.6M
Q4 2025−$3.6M$3.6M−$3.6M
Q3 2025−$3.3M$3.3M−$3.3M
Q2 2025−$4.0M$4.1M−$4.0M
Q1 2025−$4.7M−$2.7M−$4.7M
Q4 2024−$6.1M−$13.0M−$6.1M

Dogwood Therapeutics: income statement and cash flow

Dogwood Therapeutics, Q3 2026: revenue $100K. The chart follows the revenue to costs, profit and cash.

Dogwood Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.